Novartis Investigative Site

Temple, Texas 76508-0002

0 studies enrolling now · 4 studies all time

What they study most

Atherosclerosis, Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Type 2 Diabetes Mellitus

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early